CD274 and chronic obstructive pulmonary disease: Subgroup analysis further demonstrated that PD-1 monotherapy achieved optimal outcomes for both OS (HR = 0.58) and PFS (HR = 0.52), while PD-1/PD-L1 combination regimens showed weaker benefits, implying monotherapy may be more suitable for COPD populations.